Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Summary

Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.

Timeline

Start

2019-03-19

Primary completion

2019-07-23

Completion

2019-07-23

Outcome

Outcome not reported

Stopped: “Devices are not available”

Drugs

Indications